Patients with mild COVID-19 (outpatient)38 | |
Patients with moderate to severe COVID-19 with suspected or confirmed DIC without overt bleeding on chronic therapeutic anticoagulation38 | Weigh anticoagulation indication against bleeding risk, consider dose adjustment or discontinuation Majority of the authors recommend reducing anticoagulation intensity barring exceedingly high thrombosis risk
|
Patients with moderate to severe COVID-19 without overt bleeding on dual antiplatelet therapy38 | Individualised decisions for antiplatelet therapy In general, consider continuing dual antiplatelet therapy for platelet counts >50 000; reduce to single antiplatelet for platelet count 25 000–50,000; discontinue antiplatelets if platelet count <25 000
|
Patients with moderate to severe COVID-19 on existing anticoagulation for other diseases, for example, atrial fibrillation | Consider changes to therapeutic low-molecular-weight heparins while an inpatient for safer monitoring profile and less interactions with other drugs37 If breakthrough VTE occurs while on oral anticoagulants recommend changing over to low molecular weight heparins37 41 If significant renal dysfunction present, consider unfractionated heparin
|